Bartin Merkez

Researchers are evaluating the effectiveness and safety of pirtobrutinib (LOXO-305) compared to ibrutinib in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study includes participants who may have had prior treatment as well as treatment-nave participants with a specific genetic deletion (17p deletion). The study is a Phase 3, open-label, randomized trial designed to assess these treatments in different patient groups over varying durations. Participants receive either oral pirtobrutinib or oral ibrutinib. Part 1 compares these two drugs in participants with or without prior therapy, and participation can last up to six years. Part 2 focuses on pirtobrutinib alone in treatment-nave participants with 17p deletions, with participation lasting up to two years. The study carefully monitors responses to treatment, including complete and partial remissions. Throughout the study, participants undergo regular assessments to track their response to therapy, including measuring overall response rates from the start of treatment until disease progression or new treatments begin. Safety and organ function are monitored, and laboratory tests help evaluate blood counts and kidney function. The study aims to provide detailed information on how well the treatments work and their safety over the long term.

Researchers are evaluating how leg and heel massage affects pain and physiological responses in newborn babies during heel blood collection. The study compares infants who receive a leg and heel massage against those who receive routine care to see if massage lowers pain scores, heart rates, and improves oxygen saturation levels. This is a randomized controlled study focusing on newborns aged 2 to 28 days with stable vital signs. The study has two groups: an intervention group receiving leg and heel massage and a control group receiving routine care. The massage involves specific steps for stroking the baby's feet and legs to help calm the infant, with each leg and heel massaged for three minutes immediately before the heel prick procedure. Both groups undergo heel blood collection performed by the same pediatric nurse, and the procedures are standardized across participants. Participants will be assessed for pain using the Newborn Infants Pain Scale, with measurements taken 5 minutes before, during, and 5 minutes after the heel prick. Heart rate and oxygen saturation are also monitored at these times. The study aims to compare the average pain scores between groups after 9 months. Parental permission is required, and infants will be monitored closely throughout the procedure to ensure safety and accuracy of data.

Hip and knee replacement surgeries are common in older adults, but many patients experience pain, limited movement, and sleep problems after these operations. These issues can make daily activities like walking or climbing stairs difficult and reduce quality of life during recovery. Researchers are evaluating two different relaxation methods to help manage pain and improve sleep quality after hip and knee replacement surgery. The study compares virtual reality-based relaxation exercises with traditional relaxation exercises. One group of patients will use virtual reality technology to perform relaxation exercises, while the other group will perform standard relaxation exercises without virtual reality. Both approaches are delivered during the postoperative period following the joint replacement surgery. Participants will be monitored for pain intensity over the first three days after surgery. Researchers will also assess sleep quality and pain levels during this time. The study involves participants who meet specific criteria, including age, language, and health status. The results aim to determine if virtual reality-based relaxation can be a helpful alternative or support method for managing pain and sleep problems after joint replacement surgery.

Researchers are studying the effects of Adagrasib alone and combined with pembrolizumab in adults with advanced or metastatic non-small cell lung cancer (NSCLC) who have the KRAS G12C mutation. The Phase 2 part evaluates these treatments in patients who are candidates for first-line therapy, with different groups based on their PD-L1 tumor proportion scores (TPS). The Phase 3 part compares the combination of Adagrasib and pembrolizumab against pembrolizumab alone in patients with NSCLC having PD-L1 TPS of 50% or higher. In Phase 2, there are three patient groups: two with PD-L1 TPS less than 1% randomized to receive either Adagrasib monotherapy or Adagrasib plus pembrolizumab, and one group with PD-L1 TPS of 1% or higher treated with the combination. Adagrasib is given orally at doses of 400 mg twice daily or 600 mg twice daily depending on the group, while pembrolizumab is administered intravenously at 200 mg every three weeks. Phase 3 patients are randomized to receive either Adagrasib 400 mg twice daily plus pembrolizumab 200 mg every three weeks or pembrolizumab alone. Participants will undergo various assessments including brain imaging, tumor measurements, and evaluations of safety and treatment effects over 22 months in Phase 2 and 36 months in Phase 3. Researchers will monitor efficacy, safety, and drug levels, as well as patient-reported outcomes and genetic biomarkers. The study includes patients with untreated or previously treated brain metastases under specific conditions and excludes those with prior systemic treatments for advanced NSCLC or certain brain lesion characteristics.

Researchers are studying how a prenatal yoga program affects traumatic childbirth perception, self-perception, and delivery preferences in pregnant women. The study includes voluntary pregnant women aged 18 years and older who are at or beyond the 16th week of pregnancy and do not have a high-risk pregnancy diagnosis. Participants are randomly assigned to either an intervention group or a control group to compare outcomes fairly. The intervention group participates in a prenatal yoga program consisting of eight sessions, each lasting about 45 minutes, delivered twice weekly following safe prenatal exercise guidelines. The program is conducted in three separate groups of 8-12 participants each. The control group receives routine prenatal care without any additional activities from the researchers. Participants complete assessments before starting the yoga sessions, immediately after the eighth session, and again one month later. These assessments include the Traumatic Childbirth Perception Scale and other evaluations related to self-perception and delivery preferences. The study monitors participant safety and collects data throughout the intervention and follow-up periods to understand the effects of prenatal yoga.

Researchers are evaluating pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy for treating participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC). This Phase III, multisite, randomized, double-blinded trial aims to assess safety and efficacy in this population. The study includes two stages with different treatment and control arms and stratifies participants based on brain or liver metastases, smoking status, and geography. Participants will receive treatments administered by intravenous infusion, including pumitamig or atezolizumab combined with chemotherapy drugs etoposide and carboplatin, with the option to switch to cisplatin if carboplatin is not tolerated. Each stage consists of a screening period up to 21 days, followed by an induction and maintenance period lasting until confirmed disease progression, intolerable toxicity, withdrawal, study termination, or up to two years. After treatment, all participants enter a follow-up period including safety and survival visits. Throughout the study, participants undergo evaluations including assessments of overall survival for up to approximately 46 months. Researchers will monitor disease status, treatment toxicity, and participant health through scheduled visits. The study carefully tracks participant adherence and safety during treatment and follow-up to better understand the effects of the investigational therapies in ES-SCLC management.

Researchers are evaluating the effects of dual-task training on balance, exercise capacity, cognitive function, and quality of life in older adults with Type 2 Diabetes Mellitus (DM). This study focuses on whether combining cognitive exercises with conventional physical training improves these outcomes more than physical training alone or no training. The study addresses the high risk of cognitive decline and falls in this population, aiming to support more active and independent lifestyles through enhanced rehabilitation methods. Participants will be divided into three groups: a dual-task exercise group, a single-task exercise group, and a control group. Those in the dual-task group will attend 60-minute physiotherapy sessions three times a week for 8 weeks, combining aerobic, strengthening, and balance exercises with cognitive training targeting memory, verbal fluency, executive functions, calculation, and attention. The single-task group will perform the same physical exercises without cognitive tasks, while the control group will not receive these interventions. Throughout the 8-week training period, participants' balance and exercise capacity will be assessed using tests like the Time Up and Go Test and the Berg Balance Scale. Researchers will also evaluate cognitive function and quality of life changes. The study aims to monitor improvements in dual-task performance to help prevent falls and enhance daily functioning in older adults with Type 2 DM.

Researchers are evaluating how wearing surgical masks versus N95 masks affects physical symptoms caused by surgical smoke in operating room nurses. The study involved 38 nurses working in a state hospital's operating theatre unit in the Western Black Sea Region. It compared symptoms like muscle weakness, respiratory issues, and eye irritation related to surgical smoke exposure while using two different types of masks. The nurses used either standard surgical masks or N95 respirators during surgical procedures with exposure to surgical smoke. Data were collected over four weeks using forms and scales that tracked symptoms and their severity. The study observed differences in symptoms such as muscle cramps and respiratory irritation depending on the type of mask worn. Participants were monitored five days per week for four weeks both before and after surgery to measure symptom severity using a Numerical Rating Scale. Researchers collected information on symptoms including muscle weakness, myalgia, respiratory parameters, watery eyes, and redness. The study focused on how mask type influenced these physical symptoms related to surgical smoke exposure in the operating room environment.